News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
288,758 Results
Type
Article (15271)
Company Profile (298)
Press Release (273183)
Multimedia
Podcasts (99)
Webinars (12)
Section
Business (80042)
Career Advice (165)
Deals (13432)
Drug Delivery (44)
Drug Development (50852)
Employer Resources (31)
FDA (5914)
Job Trends (5196)
News (145533)
Policy (10090)
Tag
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (2)
2027 Genetown Standard (4)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (942)
Accelerated approval (29)
ADA (32)
Adcomms (14)
Allergies (106)
Alliances (21781)
ALS (167)
Alzheimer's disease (1141)
Antibody-drug conjugate (ADC) (400)
Approvals (6208)
Artificial intelligence (364)
ASCO (221)
Autoimmune disease (261)
Automation (11)
Bankruptcy (105)
Best Places to Work (4565)
BIOSECURE Act (6)
Biosimilars (123)
Biotechnology (228)
Bladder cancer (121)
Brain cancer (58)
Breast cancer (426)
Cancer (4056)
Cardiovascular disease (296)
Career advice (154)
Career pathing (10)
CAR-T (280)
CDC (8)
Celiac Disease (1)
Cell therapy (738)
Cervical cancer (24)
Clinical research (45019)
Collaboration (1462)
Company closure (3)
Compensation (764)
Complete response letters (58)
COVID-19 (1127)
CRISPR (109)
C-suite (779)
Cystic fibrosis (120)
Data (5865)
Denatured (20)
Depression (115)
Dermatology (57)
Diabetes (335)
Diagnostics (1463)
Digital health (18)
Diversity (6)
Diversity, equity & inclusion (9)
Drug discovery (264)
Drug pricing (52)
Drug shortages (3)
Duchenne muscular dystrophy (278)
Earnings (32780)
Editorial (33)
Employer branding (4)
Employer resources (29)
Events (53632)
Executive appointments (703)
FDA (8123)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (18)
Frontotemporal dementia (31)
Funding (1211)
Gene editing (228)
Generative AI (33)
Gene therapy (609)
GLP-1 (570)
Government (1184)
Grass and pollen (3)
Guidances (175)
Healthcare (6731)
Hematology (118)
HIV (28)
Huntington's disease (52)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (91)
Immunology and inflammation (237)
Immuno-oncology (83)
Indications (133)
Infectious disease (1279)
Inflammatory bowel disease (184)
Inflation Reduction Act (10)
Influenza (55)
Intellectual property (209)
Interviews (18)
IPO (7377)
IRA (13)
Job creations (870)
Job search strategy (131)
JPM (41)
Kidney cancer (9)
Labor market (32)
Layoffs (255)
Leadership (14)
Legal (1404)
Liver cancer (47)
Longevity (24)
Lung cancer (538)
Lymphoma (305)
Machine learning (33)
Management (7)
Manufacturing (527)
MASH (163)
Medical device (2717)
Medtech (2742)
Mergers & acquisitions (6790)
Metabolic disorders (927)
mRNA (163)
Multiple sclerosis (125)
NASH (14)
Neurodegenerative disease (331)
Neuropsychiatric disorders (82)
Neuroscience (2324)
Neurotech (1)
NextGen: Class of 2026 (2046)
Non-profit (878)
Now hiring (39)
Obesity (413)
Opinion (142)
Ovarian cancer (187)
Pain (135)
Pancreatic cancer (237)
Parkinson's disease (306)
Partnered (12)
Patents (393)
Patient recruitment (522)
Peanut (49)
People (27261)
Pharmaceutical (42)
Pharmacy benefit managers (6)
Phase 1 (15966)
Phase 2 (20952)
Phase 3 (13195)
Pipeline (6031)
Policy (105)
Postmarket research (853)
Preclinical (6776)
Press Release (30)
Prostate cancer (203)
Psychedelics (58)
Radiopharmaceuticals (285)
Rare diseases (883)
Real estate (1458)
Recruiting (12)
Regulatory (10593)
Reports (20)
Research institute (983)
Resumes & cover letters (20)
Rett syndrome (38)
RNA editing (28)
RSV (24)
Schizophrenia (147)
Series A (235)
Series B (165)
Service/supplier (1)
Sickle cell disease (95)
Special edition (20)
Spinal muscular atrophy (125)
Sponsored (17)
Startups (2032)
State (1)
Stomach cancer (5)
Supply chain (40)
Tariffs (19)
The Weekly (77)
Vaccines (401)
Venture capital (88)
Weight loss (223)
Women's health (47)
Worklife (2)
Date
Today (76)
Last 7 days (386)
Last 30 days (1815)
Last 365 days (17957)
2026 (8697)
2025 (18094)
2024 (20539)
2023 (22412)
2022 (26822)
2021 (27807)
2020 (23365)
2019 (16236)
2018 (11750)
2017 (13751)
2016 (11839)
2015 (14358)
2014 (10401)
2013 (7499)
2012 (7548)
2011 (7627)
2010 (7439)
Location
Africa (155)
Alabama (72)
Alaska (2)
Arizona (85)
Arkansas (6)
Asia (18702)
Australia (3201)
California (8633)
Canada (2203)
China (1031)
Colorado (309)
Connecticut (325)
Delaware (296)
Europe (40225)
Florida (1113)
Georgia (252)
Hawaii (2)
Idaho (18)
Illinois (526)
India (46)
Indiana (199)
Iowa (8)
Japan (304)
Kansas (84)
Kentucky (11)
Louisiana (17)
Maine (12)
Maryland (889)
Massachusetts (6873)
Michigan (127)
Minnesota (310)
Mississippi (3)
Missouri (35)
Montana (17)
Nebraska (6)
Nevada (47)
New Hampshire (22)
New Jersey (1961)
New Mexico (13)
New York (2146)
North Carolina (1012)
North Dakota (7)
Northern California (4384)
Ohio (216)
Oklahoma (11)
Oregon (23)
Pennsylvania (1590)
Puerto Rico (11)
Rhode Island (27)
South America (217)
South Carolina (12)
Southern California (3456)
Tennessee (51)
Texas (1183)
United States (28558)
Utah (119)
Virginia (176)
Washington D.C. (37)
Washington State (711)
West Virginia (1)
Wisconsin (58)
288,758 Results for "dyne therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Duchenne muscular dystrophy
REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies
Analysts homed in on Duchenne muscular dystrophy and myotonic dystrophy type 1 assets during first quarter earnings as major players like REGENXBIO and Novartis as well as Dyne, Wave, Solid and Sarepta near the regulatory finish line.
May 26, 2026
·
9 min read
·
Heather McKenzie
Duchenne muscular dystrophy
Dyne Plans Post-Prasad FDA Run as Duchenne Exon Skipper Sustains Benefit in Long Term Data
Dyne Therapeutics is plotting an approval application for z-rostudirsen in the back half of 2026—a push that will only be bolstered by the departure of controversial CBER chief Vinay Prasad, according to analysts at Stifel.
March 10, 2026
·
3 min read
·
Tristan Manalac
Press Releases
Dyne Therapeutics to Participate in Upcoming Investor Conferences - May 13, 2026
May 13, 2026
·
1 min read
Duchenne muscular dystrophy
Dyne’s Exon Skipper Delivers ‘Best Ever’ Functional Outcomes in Early DMD Study
Dyne’s exon-skipping therapy zeleciment rostudirsen resulted in an approximately sevenfold increase in dystrophin levels at six months and elicited functional improvements that are the “best ever” for this treatment class, Stifel analysts said.
December 8, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 11, 2026
·
11 min read
Press Releases
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 20, 2026
May 21, 2026
·
2 min read
Press Releases
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)
June 3, 2026
·
7 min read
Press Releases
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
May 26, 2026
·
7 min read
Press Releases
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 23, 2026
April 24, 2026
·
2 min read
Press Releases
Dyne Therapeutics to Participate in Upcoming March 2026 Investor Conferences
February 25, 2026
·
1 min read
1 of 28,876
Next
